{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:56:11Z","timestamp":1785297371932,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12020-021-02854-3","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T08:04:53Z","timestamp":1630051493000},"page":"239-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of the AJCC staging system of pheochromocytomas\/paragangliomas"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-2502","authenticated-orcid":false,"given":"Omar","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"2854_CR1","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"M. Fassnacht, G. Assie, E. Baudin et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1476\u20131490 (2020)","journal-title":"Ann. Oncol."},{"key":"2854_CR2","doi-asserted-by":"crossref","unstructured":"S. N\u00f6lting, N. Bechmann, D Taieb et al. Personalized management of pheochromocytoma and paraganglioma. Endocr. Rev. (2021).","DOI":"10.1210\/endrev\/bnab019"},{"key":"2854_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.humpath.2020.04.012","volume":"110","author":"LDR Thompson","year":"2021","unstructured":"L.D.R. Thompson, A.J. Gill, S.L. Asa et al. Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum. Pathol. 110, 83\u201397 (2021)","journal-title":"Hum. Pathol."},{"key":"2854_CR4","doi-asserted-by":"crossref","unstructured":"R. Garcia-Carbonero, F. Matute Teresa, E. Mercader-Cidoncha et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin. Transl. Oncol. (2021).","DOI":"10.1007\/s12094-021-02622-9"},{"key":"2854_CR5","volume-title":"Pheochromocytoma and Paraganglioma Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries","author":"Board PDQATE.","year":"2002","unstructured":"Board PDQATE. Pheochromocytoma and Paraganglioma Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries. (National Cancer Institute (US), Bethesda (MD)), 2002)"},{"key":"2854_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40618-020-01344-z","volume":"44","author":"G De Filpo","year":"2021","unstructured":"G. De Filpo, M. Maggi, M. Mannelli et al. Management and outcome of metastatic pheochromocytomas\/paragangliomas: an overview. J. Endocrinol. Investig. 44, 15\u201325 (2021)","journal-title":"J. Endocrinol. Investig."},{"key":"2854_CR7","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000\u20132018) - Linked To County Attributes - Total U.S., 1969\u20132019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission. Accessed 27 Jun 2021"},{"key":"2854_CR8","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.2147\/CMAR.S174907","volume":"10","author":"D Man","year":"2018","unstructured":"D. Man, J. Wu, Z. Shen et al. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag. Res 10, 5629\u20135638 (2018)","journal-title":"Cancer Manag. Res"},{"key":"2854_CR9","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"J.C. Yao, M. Hassan, A. Phan et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063\u20133072 (2008)","journal-title":"J. Clin. Oncol."},{"key":"2854_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/ageing\/afp221","volume":"39","author":"PN Kannegaard","year":"2010","unstructured":"P.N. Kannegaard, S. van der Mark, P. Eiken et al. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 39, 203\u2013209 (2010)","journal-title":"Age Ageing"},{"key":"2854_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1677\/ERC-08-0284","volume":"16","author":"HJ Timmers","year":"2009","unstructured":"H.J. Timmers, A.P. Gimenez-Roqueplo, M. Mannelli et al. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr. Relat. Cancer 16, 391\u2013400 (2009)","journal-title":"Endocr. Relat. Cancer"},{"key":"2854_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-017-4577-x","volume":"168","author":"O Abdel-Rahman","year":"2018","unstructured":"O. Abdel-Rahman, Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res. Treat. 168, 269\u2013275 (2018)","journal-title":"Breast Cancer Res. Treat."},{"key":"2854_CR13","doi-asserted-by":"publisher","first-page":"e0188450","DOI":"10.1371\/journal.pone.0188450","volume":"12","author":"O Abdel-Rahman","year":"2017","unstructured":"O. Abdel-Rahman, Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; a time to sub-classify stage IV? PLoS One 12, e0188450 (2017)","journal-title":"PLoS One"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02854-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T12:26:33Z","timestamp":1642422393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02854-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2854"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02854-3","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]},"assertion":[{"value":"8 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"OA: Advisory board with Eisai Canada, Roche Canada, and Lilly Canada.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}